{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:35:55Z","timestamp":1791639355124,"version":"4.3.4"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["jgaronline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jgar.2017.06.003","type":"journal-article","created":{"date-parts":[[2017,7,19]],"date-time":"2017-07-19T22:46:28Z","timestamp":1500504388000},"page":"4-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014\u20132015)"],"prefix":"10.1016","volume":"11","author":[{"given":"Michael A.","family":"Pfaller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo E.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helio S.","family":"Sader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2017.06.003_bib0005","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ijantimicag.2016.04.011","article-title":"Hot topics in the diagnosis and management of skin and soft-tissue infections","volume":"48","author":"Esposito","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2017.06.003_bib0010","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","article-title":"Practice guidelines for the diagnosis and management of skin and soft-tissue infections","volume":"41","author":"Stevens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2017.06.003_bib0015","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QCO.0000000000000239","article-title":"Epidemiology and microbiology of skin and soft tissue infections","volume":"29","author":"Esposito","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.jgar.2017.06.003_bib0020","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.pcl.2013.12.004","article-title":"Cutaneous bacterial infections caused by Staphylococcus aureus and Streptococcus pyogenes in infants and children","volume":"61","author":"Larru","year":"2014","journal-title":"Pediatr Clin North Am"},{"key":"10.1016\/j.jgar.2017.06.003_bib0025","first-page":"64","article-title":"Community-associated MRSA in the pediatric primary care setting","volume":"34","author":"Hinckley","year":"2008","journal-title":"Pediatr Nurs"},{"key":"10.1016\/j.jgar.2017.06.003_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1053\/j.spid.2004.01.003","article-title":"Antimicrobial resistance among pediatric respiratory tract infections: clinical challenges","volume":"15","author":"Jacobs","year":"2004","journal-title":"Semin Pediatr Infect Dis"},{"key":"10.1016\/j.jgar.2017.06.003_bib0035","doi-asserted-by":"crossref","first-page":"e242","DOI":"10.1097\/INF.0b013e318286c612","article-title":"The Antibiotic Resistance and Prescribing in European Children project: a neonatal and pediatric antimicrobial web-based point prevalence survey in 73 hospitals worldwide","volume":"32","author":"Versporten","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.jgar.2017.06.003_bib0040","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jac\/dkp241","article-title":"Methicillin-resistant Staphylococcus aureus strain USA300: origin and epidemiology","volume":"64","author":"Tenover","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.06.003_bib0045","doi-asserted-by":"crossref","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","article-title":"New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin","volume":"70","author":"Zhanel","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2017.06.003_bib0050","series-title":"Dalvance\u2122 package insert","author":"Durata Therapeutics US Ltd","year":"2016"},{"key":"10.1016\/j.jgar.2017.06.003_bib0055","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1007\/s10096-016-2756-z","article-title":"Dalbavancin for the treatment of paediatric infectious diseases","volume":"35","author":"Esposito","year":"2016","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2017.06.003_bib0060","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.ijantimicag.2016.04.009","article-title":"In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011\u20132013)","volume":"47","author":"Huband","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2017.06.003_bib0065","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.diagmicrobio.2010.10.031","article-title":"In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007\u20132009 study","volume":"69","author":"Karlowsky","year":"2011","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2017.06.003_bib0070","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/jac\/dkv303","article-title":"Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011\u201313)","volume":"71","author":"Mendes","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2017.06.003_bib0075","first-page":"313","article-title":"Dalbavancin for the treatment of acute bacterial skin and skin structure infections","volume":"23","author":"Esposito","year":"2015","journal-title":"Infez Med"},{"key":"10.1016\/j.jgar.2017.06.003_bib0080","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1007\/s40265-015-0430-x","article-title":"Dalbavancin: a review in acute bacterial skin and skin structure infections","volume":"75","author":"Scott","year":"2015","journal-title":"Drugs"},{"key":"10.1016\/j.jgar.2017.06.003_bib0085","series-title":"Document M07-A10","article-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.jgar.2017.06.003_bib0090","series-title":"Document M100-S","article-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2016"},{"key":"10.1016\/j.jgar.2017.06.003_bib0095","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1080\/1120009X.2016.1205309","article-title":"Deep tissue biopsy vs superficial swab culture, including microbial loading determination, in the microbiological assessment of skin and soft tissue infections (SSTIs)","volume":"29","author":"Esposito","year":"2017","journal-title":"J Chemother"},{"key":"10.1016\/j.jgar.2017.06.003_bib0100","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1517\/14656566.2015.1075508","article-title":"Dalbavancin for the treatment of acute bacterial skin and skin structure infections","volume":"16","author":"Ramdeen","year":"2015","journal-title":"Expert Opin Pharmacother"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517301157?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716517301157?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T03:59:50Z","timestamp":1535601590000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716517301157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":20,"alternative-id":["S2213716517301157"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2017.06.003","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014\u20132015)","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2017.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd on behalf of International Society for Chemotherapy of Infection and Cancer.","name":"copyright","label":"Copyright"}]}}